Article

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models

2025-03-07

Abstract excerpt

Glioblastoma multiforme (GBM) is an aggressive primary brain tumour that presents significant treatment challenges due to its complex pathology and heterogeneity. The lack of validated molecular targets is a major obstacle for discovering new therapeutic candidates, with no new effective GBM therapies delivered to patients in over two decades. Here, we report the identification of compounds that target the GBM ste...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0bd692e6-7899-568e-8edf-444d4af893f9
DOI: 10.1101/2025.03.06.641926

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular modelsDOI 10.1101/2025.03.06.641926Read

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell modelsSemantic proximity Read

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem CellsSemantic proximity Read

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read

A multistep in silico approach identifies potential glioblastoma drug candidates via inclusive molecular targeting of glioblastoma stem cellsSemantic proximity Read

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaSemantic proximity Read

Current Challenges and Opportunities in Treating GlioblastomaSemantic proximity Read

Machine learning-driven discovery of potent isocitrate dehydrogenase 1 mutant inhibitors from ultralarge ligand libraries for targeting malignant glioma.Semantic proximity Read

Gliamimic: A Longitudinal, Multimodal in Vitro Platform for Evaluating Glioblastoma Treatment Response and Relapse in Patient-derived Organoids or SpheroidsSemantic proximity Read

A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinaseSemantic proximity Read

Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.Semantic proximity Read

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesSemantic proximity Read